Infección por SARS-CoV-2 en Dos Pacientes en Tratamiento con Adalimumab
Lavieri AJ, Greco CF and Raco SC
With the onset of the SARS-CoV-2 pandemic, there is uncertainty about
whether biological agents may place patients at increased risk of infection
or a more severe disease course, either from COVID-19 or its underlying
pathology. This commentary offers patient advice recommendations
based on the current available evidence. Although there are currently no
specific data on infected patients being treated with biologics, we present
two cases, which provide information on this situation. We conclude that
biological agents would not have a negative effect on this population, in the
face of possible viral infection.
